HOLLISTER, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will participate in the following upcoming investor conference:
William Blair 42nd Annual Growth Stock Conference
June 6 – 9, 2022
Stephen Gunstream, President and Chief Executive Officer, and Matt Lowell, Chief Financial Officer, will present at 4:20 p.m. ET, on Wednesday, June 8, 2022. Gunstream and Lowell plan to discuss Company highlights, their product portfolio, market trends, key growth drivers, and long-term market opportunities.
The live audio webcast for this conference may be accessed from the Investor Relations section of the Company’s website: https://ir.teknova.com/. The webcast will be available on the Company’s website for approximately 90 days after the event.
Teknova is expediting clinical breakthroughs in life sciences by providing custom products and reagents for drug therapies, novel vaccines, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products, including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high-quality, custom, made-to-order products with short turnaround times and at scale across all stages of development, including commercialization.
Investor Contacts Matt Lowell Chief Financial Officer email@example.com +1 831-637-1100 Sara Michelmore MacDougall Advisors firstname.lastname@example.org +1 781-235-3060 Media Contact Jenn Henry Senior Vice President, Marketing email@example.com +1 831-313-1259